Seviteronel (INO-464) is a selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor (AR) inhibitor with anti-tumor activity in vitro and in vivo. This open-label phase 1 clinical study evaluated the safety, tolerability, pharmacokinetics (PK) and activity of once daily (QD) seviteronel in male chemotherapy-naïve subjects with castrate-resistant prostate cancer (CRPC).
Seviteronel was administered at 600 mg QD with dose titration (DT) and in modified 3+3 dose escalation QD cohorts at 600 mg, 750 mg, and 900 mg without DT. The primary objectives of this study were to establish safety, tolerability and the maximum tolerated dose of seviteronel in chemotherapy-naïve subjects with or without prior treatment with FDA-approved CRPC treatments, abiraterone acetate (AA) and enzalutamide (ENZA). Secondary objectives were to assess PK, PSA, tumor response and endocrine results.
Twenty-one subjects were enrolled. No dose-limiting toxicities (DLTs) were observed through 750 mg QD. Most treatment-emergent adverse events (AEs) reported at grade1-2. The most commonly reported AEs were fatigue (71%), dizziness (52%), vision blurred (38%) and dysgeusia (33%), with most AEs improving after dose reduction or dose interruption.
Once-daily seviteronel was generally well tolerated in this phase 1 study of men with CRPC, a majority of which had progressed on prior AA or ENZA, or both. Of the doses evaluated, 600 mg QD was chosen as the recommended phase 2 dose for future studies in subjects with CRPC.
Pharmacology, Toxicology and Pharmaceutical Science
2
4%
Nursing and Health Professions
2
4%
Other
6
12%
Unknown
19
38%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2026.
All research outputs
#2,178,824
of 34,350,842 outputs
Outputs from Clinical Cancer Research
#1,687
of 17,842 outputs
Outputs of similar age
#35,208
of 395,115 outputs
Outputs of similar age from Clinical Cancer Research
#40
of 201 outputs
Altmetric has tracked 34,350,842 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,115 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 201 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.
